Wednesday, 22 July 2020
Molecular microbiologists at the University of Nottingham are working with biotech firm Cyanetics and Public Health England (PHE) to discover a novel antiviral medication to effectively treat Covid-19.
In its first phase, the Innovate UK-funded project will rapidly screen strains of a harmless bacteria called Streptomyces, which is found in abundance in soil (and is even responsible for the pleasant earthy smell after it rains). Importantly, the microbe has the ability to produce natural compounds (called secondary metabolites) with potent therapeutic benefits.
Already used to produce many well-known antibiotics, Streptomyces exhibit not only antimicrobial but also valuable antiviral properties. This study aims to find a specific strain of Streptomyces that can effectively target SARS-CoV-2 - the novel coronavirus behind the current global pandemic.
To achieve this, scientists from Cyanetics will be using their laboratories in Stevenage to test over 100 Streptomyces species from a unique collection held by the Sustainable Processing Group (SPT) at the University of Nottingham.
Assistant Professor in White Biotechnology, Dr Samantha Bryan is custodian of the Streptomyces strains in question. She will lead a team of SPT researchers to support Cyanetics on the preliminary laboratory investigations in response to COVID-19.
“There is an urgent need to discover new and effective antivirals against SARS-CoV-2. Therefore, given the plethora of secondary metabolites that Streptomyces produce, they're an untapped resource for new antiviral medications. Large-scale screening, such as the one we are undertaking, increases the likelihood of identifying such antivirals.”
In phase two of the six-month project, researchers will send a shortlist of some 40 viable compounds that may inhibit in vitro replication of the SARS-CoV-2 virus in cell culture to PHE scientists for further testing towards drug development.
More information is available from Dr Samantha Bryan at Samantha.firstname.lastname@example.org or Daniel Read on Daniel.email@example.com or 01438 79104 or Emma Lowry, Media Relations Manager (Engineering) on firstname.lastname@example.org
Our academics can now be interviewed for broadcast via our Media Hub, which offers a Quicklink fixed camera and ISDN line facilities at Jubilee campus. For further information please contact a member of the Press Office on +44 (0)115 951 5798, email
For up to the minute media alerts,
follow us on Twitter
Notes to editors:
The University of Nottingham is a research-intensive university with a proud heritage. Studying at the University of Nottingham is a life-changing experience and we pride ourselves on unlocking the potential of our students. We have a pioneering spirit, expressed in the vision of our founder Sir Jesse Boot, which has seen us lead the way in establishing campuses in China and Malaysia - part of a globally connected network of education, research and industrial engagement. Ranked 103rd out of more than 1,000 institutions globally and 18th in the UK by the QS World University Rankings 2022, the University’s state-of-the-art facilities and inclusive and
disability sport provision is reflected in its crowning as The Times and Sunday Times Good University Guide 2021 Sports University of the Year. We are ranked eighth for research power in the UK according to
REF 2014. We have
six beacons of research excellence helping to transform lives and change the world; we are also a major employer and industry partner - locally and globally. Alongside Nottingham Trent University, we lead the Universities for Nottingham initiative, a pioneering collaboration which brings together the combined strength and civic missions of Nottingham’s two world-class universities and is working with local communities and partners to aid recovery and renewal following the COVID-19 pandemic.